Bank of America Securities Remains a Buy on Acumen Pharmaceuticals (ABOS)

Tip Ranks
2025.11.18 11:38
portai
I'm PortAI, I can summarize articles.

Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Acumen Pharmaceuticals with a price target of $8.00. Zemansky is a 5-star analyst with an average return of 21.3% and a 60.64% success rate. The analyst consensus on Acumen Pharmaceuticals is a Strong Buy with an average price target of $6.50.

Bank of America Securities analyst Jason Zemansky reiterated a Buy rating on Acumen Pharmaceuticals today and set a price target of $8.00.

Meet Your ETF AI Analyst

  • Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
  • Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.

According to TipRanks, Zemansky is a 5-star analyst with an average return of 21.3% and a 60.64% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Cytokinetics, Kura Oncology, and Arcus Biosciences.

Currently, the analyst consensus on Acumen Pharmaceuticals is a Strong Buy with an average price target of $6.50.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer